東陽光藥(01558.HK)獲同系退還847.5萬人幣租金 簽訂1,237.57萬人幣銷售合同
東陽光藥(01558.HK)公布,隨著中國新型肺炎疫情防控嚴峻,導致終端醫療機構患者人流急速下降,終端處方量隨之下降,可威銷量下降。公司根據市場需求情況,及時調整生產計劃,減少可威原料藥的生產。公司終止租賃乳源東陽光藥業廠房及設備,並與乳源東陽光藥業訂立退款協議,乳源東陽光藥業同意向公司退還根據廠房及設備租賃合同支付的全部租金847.5萬元人民幣(下同),藉此完全及最終解決其於廠房及設備租賃合同項下的責任。
另外,就生產磷酸奧司他韋原料藥而言,公司須負責供應化學品。由於廠房及設備租賃合同屆滿時仍有未使用完畢的化學品,為免就將化學品交回公司位於中國湖北省宜都的生產廠房產生額外運輸成本,建議向乳源東陽光藥出售相關化學品,交易作價1,237.57萬元。
乳源東陽光藥業為深圳東陽光實業的間接非全資附屬,深圳東陽光實業則持有公司母公司廣東東陽光科技控股的43.47%股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.